Voyageur Pharmaceuticals Cash Flow Statement

Financials in millions CAD. Fiscal year is December - November.

Millions CAD. Fiscal year is Dec - Nov.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Aug '25 Aug 31, 2025	Nov '24 Nov 30, 2024	Nov '23 Nov 30, 2023	Nov '22 Nov 30, 2022	Nov '21 Nov 30, 2021	Nov '20 Nov 30, 2020
Net Income	-3.13	-1.71	-1.4	-1.75	-2.05	-1.14
Depreciation & Amortization	0	0	0	0.01	0.01	0.15
Loss (Gain) From Sale of Assets	-	-	-	0.01	-	-
Asset Writedown & Restructuring Costs	0.01	0.01	0.05	-	-	-
Stock-Based Compensation	0.77	0.42	0.23	0.15	0.74	0.28
Other Operating Activities	0.18	0.05	0.01	0.11	-	-0
Change in Accounts Receivable	-0.08	-0.02	-0.01	0.02	-	0
Change in Inventory	-0.14	-0.06	-	-0	0	0
Change in Accounts Payable	-0.14	1.03	0.07	-0.19	-0.08	0.17
Change in Other Net Operating Assets	0.03	-0.03	0.05	-0.07	-0.26	0.27
Operating Cash Flow	-2.49	-0.3	-0.99	-1.72	-1.65	-0.27
Capital Expenditures	-0.21	-0.17	-0.17	-0.28	-0.44	-0.16
Sale of Property, Plant & Equipment	-	-	-	0.01	-	-
Other Investing Activities	-	-	-	-	-	0.01
Investing Cash Flow	-0.21	-0.17	-0.17	-0.27	-0.44	-0.15
Long-Term Debt Issued	-	-	-	-	-	0.23
Long-Term Debt Repaid	-	-	-	-0.02	-0.02	-0
Net Debt Issued (Repaid)	-	-	-	-0.02	-0.02	0.22
Issuance of Common Stock	3.33	0.49	1.2	1.29	3.09	0.15
Other Financing Activities	0.31	0.14	-0.06	-0.06	-0.18	-0.03
Financing Cash Flow	3.65	0.63	1.14	1.21	2.9	0.35
Miscellaneous Cash Flow Adjustments	0	-	-	-	0	-
Net Cash Flow	0.94	0.16	-0.03	-0.78	0.81	-0.07
Free Cash Flow	-2.71	-0.47	-1.17	-2	-2.09	-0.43
Free Cash Flow Per Share	-0.02	-0.00	-0.01	-0.02	-0.02	-0.01
Levered Free Cash Flow	-0.36	0.6	-0.58	-1.19	-1.05	0.02
Unlevered Free Cash Flow	-0.36	0.6	-0.58	-1.19	-1.05	0.02
Change in Working Capital	-0.33	0.93	0.11	-0.24	-0.34	0.44

Source: S&P Global Market Intelligence. Standard template. Financial Sources.